NEW YORK STATE MEDICAID PROGRAM

LABORATORY

FEE SCHEDULE

Table of Contents

GENERAL INFORMATION AND RULES	2
ORGAN OR DISEASE ORIENTED PANELS (SEE RULE 11)	10
DRUG(S) OF ABUSE TESTING	11
THERAPEUTIC DRUG ASSAYS	11
EVOCATIVE/SUPPRESSION TESTING	12
URINALYSIS	13
CHEMISTRY AND TOXICOLOGY	13
HEMATOLOGY AND COAGULATION	22
IMMUNOLOGY	24
TRANSFUSION MEDICINE	28
MICROBIOLOGY	28
CYTOPATHOLOGY	32
CYTOGENETIC STUDIES	33
SURGICAL PATHOLOGY	34
OTHER PROCEDURES	37

GENERAL INFORMATION AND RULES

- 1. The fees in this schedule apply to clinical laboratory tests selected from <u>Physician's Current Procedural Terminology (CPT)</u>, Fourth Edition, 2005 revision or the <u>Healthcare Common Procedure Coding System</u> (HCPCS), Seventeenth Edition, 2005. Reimbursement is limited to indicated uses of procedures that are FDA approved for in vitro diagnostic use or, are recognized as generally acceptable by the New York State Department of Health.
- 2. The fees in this schedule include the services of all licensed professionals required by certification in the performance of the test.
- 3. The fees in this schedule include all costs related to specimen testing, including collection, storage and transport of specimens, in addition to performance and reporting of results. Unreported instrument controls are not separately reimbursable. "By Report" (BR) reimbursement requires a statement indicating the need for the service, the type of test performed, the number and source of the specimen(s) and documentation, of the laboratory's usual and customary charge to the general public for the service.
- 4. The fees in this schedule are for **quantitative** analyses, unless otherwise specified. Mathematical calculations (eg, calculation of A/G ratio, ionized calcium, free thyroxine index (T-7) or osmolality) are not reimbursable.
- 5A. Therapeutic drug monitoring is reimbursable when quantitative determination of blood concentration is clinically relevant as a part of a regimen designed to attain and sustain therapeutic effect by maintenance of blood level within a defined range. The intensity and probability of therapeutic or toxic effect must quantitatively correlate with blood concentration. In addition, one or more of the following criteria must be satisfied: (1) there is a narrow range between those concentrations giving the desired response and those producing toxicity, (2) readily assessed alternative endpoints(eg, prothrombin time for oral anticoagulants) are lacking or (3) there is large interindividual variability in the absorption and disposition of the drug.

Therapeutic monitoring is a covered service only when performed on specimens of **blood**. Use the drug specific codes 80150-80202, 82980 or 83858. Codes 80299 or 82205 are to be used only for drugs, which meet the criteria for therapeutic monitoring, outlined above and are not listed by individual code. Codes 80299 and 82205 are billable "**By Report**" and the drug(s) must be specified in the procedure description field on the Claim Form.

Peak and trough (or predose and postdose) analyses, when clinically indicated (eg, aminoglycosides), are reimbursable as two procedures.

5B. The fee for code 80100 or 80101 covers screening of one specimen for any drugs including but not limited to alcohol, amphetamines, barbiturates, benzodiazepines, cocaine and metabolites, methadone, methaqualones, opiates, phencyclidines, phenothiazine, propoxyphenes, quinine, tetrahydrocannaboinoids (marijuana) and

tricyclic antidepressants. Screening by a broad-spectrum chromatographic procedure, which detects multiple drug classes, should be billed using code 80100. Each step in the sequential development of a chromatograph is NOT considered a separate procedure. When an analytical condition, eg, column temperature or flow rate, is changed such that additional controls must be run, subsequent analysis of the same specimen for additional drug(s) is considered a separate procedure for billing purposes. Screening by immunoassay or a chromatographic method, which detects a single drug or drug class should be billed, per procedure, using code 80101. Confirmation of presumptive positives (or presumptive negatives for compliance monitoring) MUST be by methodology of differing chemical and physical principle from that used in the initial screen. Code 80102 is billable per confirmatory procedure, regardless of analytical method. Quantitation of detected drugs is not reimbursable. Code 82205 is for therapeutic monitoring only.

- 6A. Certain laboratory procedures are often performed, either manually or on automated equipment, in combination with each other. For purposes of reimbursement, when a code defines a specific combination of procedures performed on a date of service, it is appropriate to utilize that unique code.
- 6B. When procedures for Vitamin B12 (82607) and Folate (82746 or 82747) are performed in combination, the maximum reimbursable fee for code 82746 or 82747 is \$6.25. When a procedure for Ferritin (82728) is performed in combination with Vitamin B12 or Folate, or any of the Organ or Disease Oriented Panels (80048-80076), or any of the individual chemistry analyte codes listed in the fee schedule (see Rule 6A), the maximum reimbursable fee for 82728 is \$5.70.
- 6C. When two or more Hepatitis B tests are performed in combination, reimbursement will be reduced by 50% for each test after the first. See also Rule 16. When Hepatitis A, C or D tests (codes 86692, 86708, 86709, 86803 or 87380) are performed in combination with each other or with any Hepatitis B test, the maximum reimbursable fee per Hepatitis A, C or D test is \$5.00. When multiple procedures for antigen or antibody to two or more infectious agents (codes 86602-86689 and 86698-86703 or 86710-86793) are performed in combination, reimbursement is limited to the greater fee plus 50% of the lesser fee(s). The fee for code 86701 Antibody HIV-1 includes reimbursement for up to three screen assays of a single specimen. Use code 87390 for P24 HIV antigen.
- 7A. For purposes of reimbursement based on this schedule, a complete blood count (CBC) includes a hematocrit, hemoglobin determination, RBC count, RBC indices, WBC count and a platelet count. See code 85027. For a CBC with an automated differential WBC count, use code 85025. Code 85060 requires interpretation by physician and written report.
- 7B. Codes for CBC individual components (85013, 85014, 85018, 85048 and 85049) may not be billed in conjunction with procedure codes including a CBC (85025 and 85027). The code for automated differential WBC count (85004) may not be billed in conjunction with codes 85025 and 85027.

- 8. For purposes of reimbursement, codes 86850-86905 represent examples of procedures considered to be integral parts of outpatient transfusion and hemodialysis services. No separate reimbursement will be allowed.
- 9. For **pregnancy detection** and where the reported test result is qualitative or semi-quantitative, use code 81025 or 84703. Code 84702 is reimbursable for a quantitative HCG value reported for a diagnostic use (eg, monitoring post surgical growth of germ cell neoplasm where quantitative HCG is relative to growth). Code 84702 is not reimbursable for a routine screen for pregnancy.
- 10. Appropriate billing of antibody and antigen procedures is as follows:
 - A. For antibody or antigen as specific markers of infectious disease, use the most specific code corresponding to the organism name (eg, 86618 Antibody; Borrelia burgdorferi) or the disease name (eg, 87340 Hepatitis B surface antigen).
 - B. For an infectious agent antibody or antigen not listed by name, use the "By Report" code for the type of organism (eg, 86609 Antibody; bacterium not elsewhere specified or the analytical method, e.g. 87299 Infectious agent antigen detection by immunofluorescent technique; not otherwise specified, each organism). Document the name of the organism, and, if applicable, the immunoglobulin subclass (es), on the Claim Form (See Rule 3).
 - C. For antibody other than to infectious agent(s) (eg, autoantibodies) use the most specific code corresponding to the analyte (eg, 86376 Microsomal antibody (e.g. thyroid or liver-kidney, each)).
 - D. For non-infectious agent antibody or antigen NOT listed by analyte, use the **most** specific code for the method used (eg, 86255 Fluorescent **noninfectious** agent antibody; screen each antibody); when billing "**By Report**", the name of the analyte must be documented on the Claim Form (See Rule 3).
 - E. Multiple tests to detect (1) antibodies to organisms/analytes classified more precisely than the specificity allowed by available codes, (2) antibodies in paired specimens (acute vs. convalescent), or (3) antibodies of different immunoglobulin subclasses, are reimbursable as separate procedures; multiple units of a code (eg, two units of 86658 for Coxsackie A and B species of enterovirus) may be claimed when analyses yield separately reported results for each subclassification, specimen or Iq subclass.
- 11. Organ or Disease Orientated Panel codes. Effective July 1, 2000, the panel codes 80048, 80051, 80053, 80061, 80069 and 80076 should be used to bill designated combinations of tests regardless of whether the tests are ordered and/or performed individually, as a panel, or as multiple panels at different times. If 2 or more panel codes with overlapping component tests, (i.e., 80048, 80051, 80053, 80076) are billed, the lab is not entitled to reimbursement for the duplicate tests. If one or more of the codes for chemistry tests where this rule applies are billed in combination with another and/or a panel code, total payment due for those chemistry tests is limited as follows: up to 2=\$5.03, 3-6=\$6.04, 7-9=\$7.25, 10-12=\$9.09, 13-16=\$10.00, 17-18=\$11.00, 19 or more=\$12.00.

- 12. Cytogenetic studies codes 88245, 88267 and 88269 must be billed in combination with code 88280 to report a 2-karyotype chromosome analysis as described in the quality control standards for cytogenetic licensure.
- 13. Reimbursement for immunoelectrophoresis includes payment for the electrophoretic separation and quantitation. Therefore, no separate reimbursement for code 84165 will be allowed when code(s) 86320-86325 are billed.
- 14. The molecular diagnostics codes (83890-83912) are reimbursable for **DNA-based genetic testing** performed as (1) a family study of up to six individuals (up to a maximum of six probes or primer pairs per individual) to determine the genetic carrier/disease status of an individual patient or a fetus as part of a comprehensive program of genetic counseling and where indicated by familial medical history or adjunctive prenatal testing **OR** (2) an individual study by diagnostic deletion analysis of a patient affected by a genetic disorder. DNA-based testing defined under State licensure as investigational for a certain disease is not reimbursable. Codes 83890-83912 are not reimbursable for non-genetic applications such as microbial detection or quantification, or testing for acquired changes in genetic material (eg, T or B cell markers, immunoglobulin heavy or light chain rearrangements associated with malignancy). The listed fee for code 83912 is for interpretation and report of a single specimen, eg, a carrier study. When using code 83912 to claim reimbursement for pedigree or linkage analysis, submit a report according to "By Report" instructions in Rule 3.
- 15. Code 82105, 82106, 82378, 83950, 84066, 84153, 84154, 84702 or 86316 is reimbursable for an **oncofetal antigen** (tumor marker) procedure used as an adjunctive test with other accepted tests in monitoring for tumor growth recurrence in a patient who has had a tumor irradiated or surgically removed. Codes 82105 and 82106 are also reimbursable for alpha-fetoprotein testing used for prenatal (nondiagnostic) gestational age dependent screening for neural tube defects. Code 86316 for immunoassay for a tumor antigen not elsewhere specified, eg, CA 50, is billable "**By Report**". When a procedure for (CEA) carcinoembryonic antigen (82378) is performed in combination with Comprehensive Metabolic Panel (code 80053) the maximum reimbursable fee for code 82378 is \$8.00. A test for an oncofetal antigen (tumor marker) is reimbursable for diagnostic purposes only when used in accordance with the FDA approval criteria for its use. When 84153 and 84152 or 84154 are billed in combination, the maximum fee for 84152 or 84154 is \$21.35.
- 16. Claims for reimbursement for procedures generally considered to be follow-up testing must be supported by reporting a specific (presumptive) diagnosis which considers the results of the initial test(s) as well as the patient's history, symptoms, etc. The ordering practitioner must supply such diagnosis, or reason for the patient encounter, to the laboratory. For example:
 - A. Code 82172 is reimbursable when performed for diagnostic purposes for a patient with documented elevated total cholesterol (>240 mg/dl) and an abnormally low HDL cholesterol level (< 35 mg/dl) and/or documented family history of coronary artery disease (CAD). A test for apolipoprotein(s) is **not**

- reimbursable when used as a **screening** procedure for CAD risk assessment.
- B. Thyroid function tests other than "screen" tests for clinically suspected thyroid dysfunctions are reimbursable only when indicated for differential diagnosis, to resolve disagreement with documented clinical impressions, to resolve equivocal results or to monitor therapeutic regimens of diagnosed thyroid-dysfunctional patients. For purposes of this rule, a "screen" test is either total thyroxine (84436) or free thyroxine index (84436 + 84479) or sensitive-TSH (84443).
- C. Serologic markers that are clinically indicated for staging, management or prognosis of viral hepatitis B are reimbursable only when it is determined by initial diagnostic testing that the patient has type B hepatitis.
- 17. The fee for presumptive identification of microbial culture isolates includes reimbursement for all procedures used to presumptively identify the organism, including stains. When definitive identification is medically necessary and additional methods are used for definitive identification, (eg, molecular methods) use code 87076 or 87077, as applicable, in addition to the appropriate code for isolation (87040 87075).
- 18. Lymphocyte evaluation by immunophenotyping is reimbursable for analysis of lymphocyte subpopulations for monitoring of disease activity and therapeutic response in, for example, immunodeficiency or autoimmune disease, or cancer. Only those antibodies or "markers" FDA-approved or cleared and/or approved by the Department are reimbursable as follows:
 - A. Bill 1 unit of code 86360 when the lab performs an "abbreviated lymphocyte" analysis panel* by 2-color flow cytometric analysis or any acceptable tube combination out of the possible four analysis tubes by 3 or 4-color flow cytometric analysis, and reports absolute CD4 counts with CD8 counts;
 - B. Bill 2 units of code 86360 when the lab performs a "full lymphocyte" analysis panel* by 2, 3 or 4-color flow cytometric analysis and reports absolute CD4 counts with CD8 counts. Codes 86355, 86357, 86359, 88184, 88185 and 88187 through 88189 are not reimbursable for a 'full lymphocyte' analysis panel when only performing absolute CD4 counts with CD8 counts;
 - C. Bill 1 unit of code 86361 when the lab performs lymphocyte subpopulation counts by a method other than flow cytometry or microscopy, and reports only absolute CD4 counts with or without CD8 counts;
 - D. Bill 1 unit of one or more of the codes 86355, 86357, 86359, 86367, 88184 and whenever appropriate, 1 or more units of 88185, when the lab performs flow cytometric testing using multiple markers (e.g. lymphoma/leukemia testing). When CD4/CD8 analysis is included, 1 unit of 86360 should be billed in addition, and when CD4 analysis is included (without CD8), bill 1 unit of 86361 in addition. Codes 86360 and 86361 may not be billed for the same date of service. 88184 and 88185 should be used for unlisted markers, including markers used to draw gates, set cursors and monitor variability. Bill 1 unit of the appropriate interpretation code (88187 through 88189) based on the total number of markers performed
 - E. Bill code 88346 or 88347 when the lab performs microscopic or other non-flow

cytometric subset analysis using tagged antibody (ies); bill 1 unit of code 88346 or 88347 per marker.

- * "Abbreviated lymphocyte" and "full lymphocyte" panels are as defined by the New York State Cellular Immunology Proficiency Testing Program.
- 19. Code **86341 Islet cell antibody** is reimbursable when used to differentiate type I from type II diabetes in patients with equivocal clinical presentation. It is <u>not</u> reimbursable when used as a predicator of disease, eg, in first-degree relatives of persons with diabetes mellitus.
- 20. Code 87536 HIV-1 quantitation is reimbursable when used in patient management to predict clinical outcomes, to predict risk of disease progression, and/or to provide information for a decision to initiate antiretroviral drug therapy or to change treatment regimes. This test is allowed as clinically indicated up to a <u>maximum</u> of six per year.
- 21. HIV genotypic and phenotypic drug resistance testing is a covered service when clinically indicated, up to a maximum of three tests (any combination of codes 87901 and/or 87903) per year.

Effective for dates of service on and after **April 1, 2002**, code 87903 reimburses \$675.29 for resistance determinations of up to 10 antiviral drugs. Code 87904 should be used in addition to 87903 to claim reimbursement for additional drug resistance determinations, using one unit for each additional five drugs. Code 87904 does not count toward the 3 tests per year maximum.

When codes 87901 and 87903 are billed with the same date of service, the maximum reimbursable fee for the combination of 87901 and 87903 is \$925.29, i.e., \$100 less than the additive maximum fees for the codes.

- 22. For instrumented screening of PAP smears (codes 88174 and 88175), the following definitions apply:
 - A. For code 88174, "screening by automated system" means primary examination by a slide profiling system without human review and primary examination by human review of all fields of vision selected by a locations-guidance system, with or without quality assurance manual or automated re-screening.
 - B. For code 88175, "screening by automated systems and manual rescreening" means primary examination by human review of all or some fields of vision selected by a location guidance system, and, in addition, full slide review (e.g., AutoScan mode engaged), with or without quality assurance manual or automated rescreening.

23. Effective September 1, 2004, travel expenses associated with in-home phlebotomy services, i.e., blood draws, is reimbursable using code P9604. The recipient must be eligible for in-home phlebotomy as documented by a qualified ordering practitioner and defined below.

A recipient is eligible for in-home phlebotomy if:

- The recipient is homebound, which means he or she has a condition due to illness or injury that precludes access to routine medical services outside of his/her residence without special arrangements for transportation, i.e., ambulance, ambulette, and taxi with assistance in areas where public transportation is unavailable; or has a condition that makes leaving the residence medically contraindicated; and,
- 2. The recipient is participating in a Medicaid-covered home care program or is currently receiving a Medicaid-covered home care service, i.e., personal care services, certified home health agency (CHHA) services, consumer-directed personal assistance services, or the Long Term Home Health Care Program (LTHHCP).

Travel expenses are NOT a covered service if they are solely to:

- 1. Draw blood from patients in a skilled nursing facility;
- Draw blood from a recipient who receives medical services in his or her residence from a professional whose scope of practice authorizes the drawing of blood; or,
- 3. Pick-up and transport a specimen collected by a home health care provider or anyone other than a laboratory representative.

The laboratory is entitled to only one fee for one-way or round-trip travel to a single address, regardless of the number of specimens collected or the number of recipients drawn at that location. There is a limit of 12 claims per recipient per year for in-home phlebotomy service; this allows for 12 round-trips or 12 one-way trips, or any combination of no more than 12 round or one-way trips. The number of specimens collected per trip must be documented.

To calculate the appropriate reimbursement amount for claiming travel to and from in-home phlebotomy services, multiply the number of trips or stops (including the return trip to the laboratory) by the fee and divide this amount by the number of patients seen. The laboratory will pro-rate when the claim is submitted based on the number of patients seen on that trip. The "same address" is defined as a building or complex with the same entrance and egress off of a public road, such as an apartment complex.

Rules for billing, including pro-rating for multiple recipients:

- **1. One recipient at one site:** A laboratory representative travels from the laboratory to the home of one recipient and returns to the laboratory without making any other stops. The trip out and back is paid as a round-trip. The laboratory should submit a single line claim for \$15.00 (2 x \$7.50 = \$15.00).
- **2.** One recipient at each of multiple sites: A laboratory representative travels in a circuit from the laboratory to the home of each of six recipients and returns to the laboratory. Each segment is paid as a one-way trip at a flat rate of \$7.50. The laboratory is entitled to a total of \$52.50 ($7 \times $7.50 = 52.50) but, since a separate claim must be submitted for each recipient, \$52.50 must be divided by the number of recipients, which is six. Each of the six recipient claims would be submitted for **\$8.75**.
- **3. Multiple recipients at a single address:** A laboratory representative travels from the laboratory to an apartment complex, draws blood from six recipients and returns to the laboratory. The laboratory is entitled to one round trip fee of \$15.00, but, since a separate claim must be submitted for each recipient, the \$15.00 must be divided by the number of recipients, which is six. Each of the six recipients' claims would be submitted for **\$2.50.**
- **4. Multiple recipients at one address + one recipient at each of several additional sites:** A laboratory representative travels from the laboratory to an apartment complex and draws blood from three recipients; he then continues his circuit to three separate residences, and draws blood from one recipient at each, and returns to the laboratory. The laboratory should bill as follows:

The laboratory is entitled to \$7.50 for the trip segment from the laboratory to the apartment complex;

For each of the three recipients drawn at separate addresses, the laboratory is entitled to \$7.50 trip segment. The laboratory is also entitled to \$7.50 for the return to the laboratory. The total would be four times \$7.50, or \$30.00.

The total number of stops are 5 (one stop from the laboratory to the apartment complex, stops at three recipients' homes and the return trip to the laboratory). The laboratory is entitled to a total of \$37.50 (5 x \$7.50 = \$37.50), but since a separate claim must be submitted for each recipient, \$37.50 must be divided by the number of recipients which is six. Each of the six recipient's claims would be submitted for \$6.25.

CODE	DESCRIPTION	FEE
ORGA 80048	AN OR DISEASE ORIENTED PANELS (see Rule 11) Basic metabolic panel This panel must include the following: Calcium (82310), Carbon dioxide (82374), Chloride (82435), Creatinine (82565), Glucose(82947), Potassium (84132),	7.25
80051	Sodium (84295), Urea Nitrogen (BUN)(84520) Electrolyte panel This panel must include the following: Carbon dioxide (82374), Chloride (82435), Potassium (84132), Sodium (84295)	6.04
80053	Comprehensive metabolic panel This panel must include the following: Albumin (82040), Bilirubin, total (82247), Calcium (82310), Carbon dioxide (bicarbonate) (82374), Chloride (82435), Creatinine (82565), Glucose (82947), Phosphatase, alkaline (84075), Potassium (84132), Protein, total (84155), Sodium (84295), Transferase, alanine amino (ALT)(SGPT)(84460), Transferase, aspartate amino (AST)(SGOT)(84450), Urea Nitrogen	10.00
80061	(BUN)(84520) Lipid panel This panel must include the following: Cholesterol, serum, total (82465), Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol)(83718), Triglycerides (84478)	6.04
80069	Renal function panel This panel must include the following: Albumin (82040), Calcium (82310), Carbon dioxide (bicarbonate)(82374), Chloride (82435), Creatinine (82565), Glucose (82947), Phosphorus, inorganic (phosphate)(84100), Potassium (84132), Sodium (84295), Urea nitrogen (BUN)(84520)	9.09
80076	Hepatic function panel This panel must include the following: Albumin (82040), Bilirubin, total (82247), Bilirubin, direct (82248), Phosphatase, alkaline (84075), Protein, total (84155), Transferase, alanine amino (ALT)(SGPT)(84460), Transferase, aspartate amino (AST)(SGOT)(84450)	7.25

<u>CODE</u> <u>DESCRIPTION</u> <u>FEE</u>

DRUG(S) OF ABUSE TESTING

Qualitative screening tests are reimbursable per procedure, not method or analyte, using code 80100 or 80101. Use code 80102 for each procedure necessary for confirmation. See Rule 5B.

80100	Drug screen, qualitative; multiple drug classes chromatographic	5.00
	method, each procedure.	
80101	single drug class method(eg, immunoassay, enzyme assay),	1.25
	each drug class.	
80102	Drug, confirmation, each procedure.	5.00

THERAPEUTIC DRUG ASSAYS

Quantitative therapeutic drug monitoring is reimbursable only when performed on specimens of **blood** as outlined in Rule 5A.

(For barbiturates not specifically listed by name, use 82205)

80150	Amikacin	10.50
80152	Amitriptyline	10.50
80156	Carbamazepine; total	10.50
80157	free	10.50
80158	Cyclosporine	10.50
80160	Desipramine	10.50
80162	Digoxin	10.50
80164	Dipropylacetic acid (valproic acid)	10.50
80166	Doxepin	10.50
80168	Ethosuximide	10.50
80170	Gentamicin	10.50
	(For glutethimide, use 82980)	
80173	Haloperidol	10.50
80174	Imipramine	10.50
80178	Lithium	7.04
	(For methsuximide, use 83858)	
80182	Nortriptyline	10.50
80184	Phenobarbital	10.50
80185	Phenytoin; total	10.50
80186	free	10.50
80188	Primidone	10.50
80194	Quinidine	10.50
80196	Salicylate	8.30
80195	Sirolimus	10.50
80197	Tacrolimus	10.50
80198	Theophylline	8.00
80200	Tobramycin	10.50
80202	Vancomycin	10.50
80299	Quantitation of drug, not elsewhere specified (See Rule 5A)	BR

<u>CODE</u> <u>DESCRIPTION</u> <u>FEE</u>

EVOCATIVE/SUPPRESSION TESTING

The following tests involve the administration of evocative or suppressive agents and the baseline and subsequent measurement of their effects on chemical constituents. The costs of the evocative or suppressive agents are not included in the fee, with the exception of oral glucose for codes 80430 and 82950 – 82953. Reference to a particular analyte in the code description (eg, cortisol x 2) indicates the minimum number of times that particular analysis must be performed in order to claim reimbursement for the test. When multiple evocative or suppressive tests are performed in combination reimbursement is limited to the greater fee plus 50% of the lesser fee(s).

80400	ACTH stimulation panel; for adrenal insufficiency (cortisol x 2)	33.90
80402	for 21 hydroxylase deficiency (cortisol x 2 and 17 hydroxyprogesterone x 2)	97.90
80406	for 3 beta-hydroxydehydrogenase deficiency (cortisol x 2 and 17 hydroxypregnenolone x 2)	91.90
80410	Calcitonin stimulation panel (eg, calcium, pentagastrin) (calcitonin x 3)	101.04
80414	Chorionic gonadotrophin stimulation panel; testosterone response (testosterone x 2)	65.80
80415	estradiol response (estradiol x 2)	65.42
80416	Renal vein renin stimulation panel	165.00
	(eg, captopril) (renin x 6)	
	(For a single measurement of blood cortisol after administration of	
	dexamethasone, use 82533)	
80420	Dexamethasone suppression panel, 48 hour	64.80
	(free cortisol/urine x 2 and cortisol x 2)	
	(For gastrin-secretin stimulation test, use 82938)	
	(For glucose tolerance test, use 82951 +/-82952)	
80426	Gonadotropin releasing hormone stimulation panel (follicle stimulating hormone (FSH) x 4 and luteinizing hormone (LH) x 4)	150.92
80428	Growth hormone stimulation panel (eg, arginine infusion,	73.00
	I-dopa administration) (human growth hormone (HGH) x 4)	
80430	Growth hormone suppression panel (includes glucose)	76.84
	(glucose x 3 and human growth hormone (HGH) x 4)	
80432	Insulin-induced C-peptide suppression panel	109.14
	(insulin x 1 and C-peptide x 5 and glucose x 5)	
80436	Metyrapone panel (cortisol x 2 and 11-deoxycortisol x 2)	57.90
80438	Thyrotropin releasing hormone (TRH) stimulation panel; one hour	18.00
	(thyroid stimulating hormone (TSH) x 3)	
	(For tolbutamide tolerance test, use 82953)	
	(For xylose tolerance test, use 84620)	

CODE	DESCRIPTION	<u>FEE</u>
URINALYSIS		
81000	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, ph, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy	4.00
81001 81002	automated, with microscopy non-automated, without microscopy	4.00 2.00
81003 81007 81015 81025	automated, without microscopy Urinalysis; bacteriuria screen, except by culture or dipstick microscopic only Urine pregnancy test, by visual color comparison methods (For microalbumin, use 82043, 82044)	2.00 2.00 2.00 2.00
CHEM	ISTRY AND TOXICOLOGY	
82009 82013 82016 82017	Acetone or other ketone bodies, serum; qualitative Acetylcholinesterase Acylcarnitines; qualitative, each specimen quantitative, each specimen	0.50 15.44 19.16 23.31
82024	(For carnitine, see 82379) Adrenocorticotropic hormone (ACTH)	53.38
82040 82042	Albumin; serum (see Rule 11) urine or other source, quantitative, each specimen (see Rule 11)	5.03 5.03
82043 82044	urine, microalbumin, quantitative (see Rule 11) urine, microalbumin, semiquantitative (eg, reagent strip assay) (see Rule 11)	5.03 0.50
82045 82088	ischemia modified Aldosterone	11.94 48.84
82103 82104	Alpha-1-antitrypsin; total phenotype	12.50 13.72
82105 82106	Alpha-fetoprotein; serum amniotic fluid (For alpha-2-macroglobulin, see 86329)	6.50 10.00
82108 82120 82127	Aluminum Amines, vaginal fluid, qualitative Amino acids; single, qualitative, each specimen (not elsewhere specified)	30.90 2.00 9.20
82128 82131 82136 82139 82140	multiple, qualitative, each specimen (not elsewhere specified) single, quantitative, each specimen, (not elsewhere specified) Amino acids, 2 to 5 amino acids, quantitative, each specimen Amino acids, 6 or more amino acids, quantitative, each specimen Ammonia (blood)	9.20 14.00 14.00 14.00 19.26
82143 82150	Amniotic fluid scan (spectrophotometric) Amylase (see Rule 11)	8.99 5.03

CODE	DESCRIPTION	FEE
82154 82157	Androstanediol glucuronide Androstenedione	30.54 30.00
82172	(For androsterone, see ketogenic steroids 83593) Apolipoprotein, each (See Rule 16)	15.93
82175	Arsenic	22.00
82180	Ascorbic acid (Vitamin C), blood	9.90
82205	Barbiturates, not elsewhere specified (therapeutic monitoring only) (See Rule 5)	BR
82232	Beta-2 microglobulin	12.50
82239	Bile acids; total	13.05
82240	cholylglycine	16.25
82247	Bilirubin; total (see Rule 11)	5.03
82248	direct (see Rule 11)	5.03
82261	Biotinidase, each specimen	15.93
82270	Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (ie, patient was provided three cards	3.40
82274	or single triple card for consecutive collection) Blood, occult, by fecal hemoglobin determination by immunoassay,	3.40
· · ·	qualitative, feces, 1-3 simultaneous determinations	00
82300	Cadmium	15.80
82306	Calcifediol (25-OH Vitamin D-3)	36.60
82308	Calcitonin	35.68
82310	Calcium; total (see Rule 11)	5.03
82330	ionized (see Rule 11)	5.03
82340	urine quantitative, timed specimen (see Rule 11)	6.38
82355	Calculus; qualitative analysis	14.52
82360	quantitative analysis, chemical	16.31
82365	infrared spectroscopy	12.39
82370	x-ray diffraction	13.08
82373	Carbohydrate deficient transferrin	7.89
82374	Carbon dioxide (bicarbonate) (see Rule 11)	5.03
82375	Carbon monoxide, (carboxyhemoglobin); quantitative	11.00
82378	Carcinoembryonic antigen (CEA) (See Rule 15)	24.35
82379	Carnitine (total and free), quantitative, each specimen	10.50
82382	Catecholamines; total urine	18.40
82383	blood fractionated	18.40
82384 82390	Ceruloplasmin	18.40 8.10
82435	Chloride; blood (see Rule 11)	5.03
82436	urine (see Rule 11)	5.03
82438	other source (see Rule 11)	5.03
02700	(For sweat collection by iontophoresis, use 89230)	5.05
82465	Cholesterol, serum or whole blood, total (see Rule 11)	5.03
	(For high density lipoprotein (HDL), see 83718)	

CODE	DESCRIPTION	<u>FEE</u>
82480	Cholinesterase; serum	8.00
82495	Chromium	25.68
82507	Citrate	25.30
82523	Collagen cross links, any method	20.00
82525	Copper	15.70
82530	Cortisol; free	18.45
82533	total	18.45
82550	Creatine kinase (CK),(CPK); total (see Rule 11)	5.03
82552	isoenzymes	9.40
82553	MB fraction only	8.05
82565	Creatinine; blood (see Rule 11)	5.03
82570	other source (see Rule 11)	5.03
82575	clearance (see Rule 11)	5.83
82595	Cryoglobulin, qualitative or semi-quantitative (eg, cryocrit)	5.48
82607	Cyanocobalamin (Vitamin B-12); (see Rule 6B)	12.50
82608	unsaturated binding capacity	19.80
82615	Cystine and homocystine, urine, qualitative	7.00
82626	Dehydroepiandrosterone (DHEA)	23.82
82627	Dehydroepiandrosterone-sulfate (DHEA-S)	23.82
82634	Deoxycortisol, 11-	15.00
82656	Elastase, pancreatic (EL-1), fecal, qualitative or semi-quantitative	5.20
82668	Erythropoietin (EPO)	17.06
82670	Estradiol	34.21
82672	Estrogens; total	25.30
82677	Estriol	17.50
82679	Estrone	25.30
	(For etiocholanolone, see ketogenic steroids 83593)	
82705	Fat or lipids, feces; qualitative	5.22
82710	quantitative	18.70
82726	Very long chain fatty acids	88.60
82728	Ferritin	14.75
82731	Fetal fibronectin, cervicovaginal secretions, semi-quantitative	71.20
82746	Folic acid; serum (see Rule 6B)	12.50
82747	RBC (see Rule 6B)	12.50
	(For fructosamine, use 82985)	
82759	Galactokinase, RBC	29.69
82760	Galactose	14.89
82775	Galactose-1-phosphate uridyl transferase; quantitative	29.12
82784	Gammaglobulin; IgA, IgD, IgG, IgM, each	10.50
82785	IgE	12.50
82787	immunoglobulin subclasses (IgG1, 2, 3 or 4), each	5.90

CODE	DESCRIPTION	FEE
82803	Gases, blood, any combination of (two or more) pH, pC02, p02, C02, HC03 (including calculated 02 saturation);	16.20
82805	with 02 saturation, by direct measurement, except pulse oximetry	23.89
82810	Gases, blood, O2 saturation only, by direct measurement, except pulse oximetry	10.69
82820	Hemoglobin-oxygen affinity (pO2 for 50% hemoglobin saturation with oxygen)	10.08
82938	Gastrin after secretin stimulation	19.10
82941	Gastrin	21.10
82943	Glucagon	17.42
82945	Glucose, body fluid, other than blood (see Rule 11)	5.03
82947	Glucose; quantitative, blood(except reagent strip) (see Rule 11)	5.03
82948	blood, reagent strip	2.00
82950	post glucose dose (includes glucose)	5.69
82951 82952	tolerance test (GTT), three specimens (includes glucose)	6.84 1.40
82953	tolerance test, each additional beyond three specimens tolbutamide tolerance test (glucose x 7 and insulin x 7)	73.75
02933	(includes glucose) (see explanatory paragraph page 5-9)	13.13
82955	Glucose-6-phosphate dehydrogenase (G6PD); quantitative	13.40
82960	screen	3.00
82963	Glucosidase, beta	29.69
82965	Glutamate dehydrogenase	8.79
82977	Glutamyltransferase, gamma (GGT) (see Rule 11)	5.03
82980	Glutethimide	10.50
82985	Glycated protein	10.64
	(For gonadotropin, chorionic, see 81025, 84702, 84703)	
83001	Gonadotropin; follicle stimulating hormone (FSH)	22.10
83002	luteinizing hormone (LH)	20.88
83003	Growth hormone, human (HGH) (somatotropin)	20.50
	(For multiple measurements of growth hormone in stimulation/	
92000	suppression tests, see 80428 – 80430)	02.00
83009	Helicobacter pylori, blood test analysis for urease activity, non-radioactive isotope (EG, C-13) (includes kit)	93.09
83010	Haptoglobin; quantitative	13.81
83013	Helicobacter pylori; breath test analysis for urease activity, non-	93.09
03013	radioactive isotope (includes kit)	93.09
83015	Heavy metal (arsenic, barium, beryllium, bismuth,	26.03
	antimony, mercury); screen	
83020	Hemoglobin fractionation and quantitation; electrophoresis	14.70
83021	(eg, A2, S, C, and/or F) chromatography (eg, A2, S, C, and/or F)	20.61
03021	omornatography (eg. Δz , δ , δ , and/or Γ)	20.01

CODE	DESCRIPTION	FEE
83030	Hemoglobin; F(fetal), chemical	3.75
83036	glycosylated (A1C)	10.64
	(for fecal hemoglobin detection by immunoassay, use 82274)	
83050	methemoglobin, quantitative	3.75
83051	plasma	3.75
83080	b-Hexosaminidase, each assay (Tay Sachs diagnostic/carrier testing)	42.00
83090	Homocystine	18.54
83150	Homovanillic acid (HVA)	6.25
83497	Hydroxyindolacetic acid, 5-(HIAA)	17.52
83498	Hydroxyprogesterone, 17-d	35.00
83500	Hydroxyproline; free	31.30
83505	total	33.59
83525	Insulin; total	12.50
83527	free	12.50
83540	Iron (see Rule 11)	5.03
83550	Iron binding capacity (see Rule 11)	5.03
83586	Ketosteroids, 17- (17-KS); total	9.40
83593	fractionation	11.45
83605	Lactate (lactic acid)	9.30
83615	Lactate dehydrogenase (LD),(LDH); (see Rule 11)	5.03
83625	isoenzymes, separation and quantitation	9.40
83630	Lactoferrin, fecal; qualitative	5.20
83631	quantitative	11.28
83655	Lead Fotal lung maturity apparament: locithin appingamualin (L/S) ratio	15.00
83661 83662	Fetal lung maturity assessment; lecithin sphingomyelin (L/S) ratio foam stability test	23.90 20.56
83663	fluorescence polarization	10.46
83664	lamellar body density	5.22
83690	Lipase	5.75
83718	Lipoprotein, direct measurement; high density cholesterol	5.03
02727	(HDL cholesterol) (see Rule 11)	22.77
83727	Luteinizing releasing factor (LRH) Magnesium (see Rule 11)	23.77
83735 83785	Manganese	5.03 30.40
83825	Mercury, quantitative	20.80
83835	Metanephrines	22.36
83858	Methsuximide	10.50
83864	Mucopolysaccharides, acid; quantitative	20.15
83866	screen	11.94
83880	Natriuretic peptide	34.07
23000	(For coding guidelines for molecular diagnostic services,	3 1.07
	83890-83912, see Rule 14)	

CODE	DESCRIPTION	FEE
83890	Molecular diagnostics; molecular isolation or extraction	5.54
83891	isolation or extraction of highly purified nucleic acid	5.54
83892	enzymatic digestion	5.54
83893	dot/slot blot production	5.54
83894	separation by gel electrophoresis	5.54
00000	(eg, agarose, polyacrylamide)	E E 4
83896	nucleic acid probe, each	5.54
83897 83898	nucleic acid transfer (eg, Southern, Northern)	5.54 15.89
03090	amplification of patient nucleic acid, each nucleic acid sequence	15.69
83900	amplification of patient nucleic acid, multiplex, first two nucleic acid sequences	31.78
83901	amplification of patient nucleic acid, multiplex, each additional nucleic acid sequence (list separately in addition to code for	15.89
00000	primary procedure) (See Rule 14)	40.45
83902	reverse transcription	13.45
83903	mutation scanning, by physical properties (eg, single strand conformational polymorphisms (SSCP), heteroduplex, denaturing gradient gel electrophoresis (DGGE), (RNA'ase A),	23.42
83904	single segment, each mutation identification by sequencing, single segment,	23.42
03904	each segment	23.42
83905	mutation identification by allele specific transcription,	23.42
	single segment, each segment	
83906	mutation identification by allele specific translation,	23.42
	single segment, each segment	
83907	lysis of cells prior to nucleic acid extraction (eg, paraffin	5.54
	embedded tissue)	
83908	signal amplification of patient nucleic acid, each nucleic acid	15.89
	sequence (for multiplex amplification, see 83900, 83901)	00.40
83909	separation and identification by high resolution technique (eg,	23.42
83912	capillary electrophoresis) interpretation and report (see Rule 14)	20.00
83914	Mutation identification by enzymatic ligation or primer extension,	23.42
03317	single segment, each segment (eg, oligonucleotide ligation assay	20.72
	(OLA), single base chain extension (SBCE), or allele-specific primer	
	extension (ASPE))	
S3818	Complete gene sequence analysis; BRCA 1 gene	BR
S3819	BRCA 2 gene	BR
S3820	Complete BRCA1 and BRCA2 gene sequence analysis for	BR
	Susceptibility to breast and ovarian cancer	
S3822	Single mutation analysis (in individual with a known BRCA1 or	BR
	BRCA2 mutation in the family) for susceptibility to breast and ovarian cancer	

CODE	DESCRIPTION	<u>FEE</u>
S3823	Three-mutation BRCA1 and BRCA2 analysis for susceptibility to breast and ovarian cancer in Ashkenazi individuals	BR
S3828	Complete gene sequence analysis; MLH1 gene	BR
S3829	Complete gene sequence analysis; MLH2 gene	BR
S3830	Complete MLH1 and MLH2 gene sequence analysis for hereditary	BR
	nonpolyposis colorectal cancer (HNPCC) genetic testing	
S3831	Single-mutation analysis (in individual with a known MLH1 and	BR
	MLH2 mutation in the family) for hereditary nonpolyposis colorectal	
S3833	cancer (HNPCC) genetic testing Complete APC gene sequence analysis for susceptibility to familial	BR
03033	adenomatous polyposis (FAP) and attenuated FAP	DIX
S3834	Single-mutation analysis (in individual with a known APC mutation in	BR
	the family) for susceptibility to familial adenomatous polyposis	
	(FAP)and attenuated FAP	
S3835	Complete gene sequence analysis for cystic fibrosis genetic testing	BR
S3840	DNA analysis for germline mutations of the RET proto-oncogene for	BR
	susceptibility to multiple endocrine neoplasia type 2	
S3842	Genetic testing for von Hippel-Lindau disease	BR
S3843	DNA analysis of the F5 gene for susceptibility to Factor V Leiden thrombophilia	BR
S3844	DNA analysis of the connexin 26 gene (GJB2) for susceptibility to	BR
00044	congenital, profound deafness	DIX
S3845	Genetic testing for alpha-thalassemia	BR
S3846	Genetic testing for hemoglobin E beta-thalassemia	BR
S3847	Genetic testing for Tay-Sachs disease	BR
S3848	Genetic testing for Gaucher disease	BR
S3849	Genetic testing for Niemann-Pick disease	BR
S3850	Genetic testing for sickle cell anemia	BR
S3851	Genetic testing for Canavan disease	BR
S3852	DNA analysis for APOE epilson 4 allele for susceptibility to Alzheimer's disease	BR
S3853	Genetic testing for myotonic muscular dystrophy	BR
83918	Organic acids; total, quantitative, each specimen	22.75
83919	qualitative, each specimen	22.75
83921	Organic acid, single, quantitative	22.75
83930	Osmolality; blood (see Rule 4)	6.04
83935	urine (see Rule 4)	6.04
83945	Oxalate	11.90
83950	Oncoprotein, HER-2/neu (see Rule 15)	71.20
83970	Parathormone (parathyroid hormone)	52.32
84030	Phenylalanine (PKU), blood	7.61
84060 84066	Phosphatase, acid; total (see Rule 11) prostatic (see Rule 15)	5.03 9.99
04000	prostatio (see rule 19)	9.99

84078 heat stable (total not included) (see Rule 11) 84080 isoenzymes 84081 Phosphatidylglycerol (separate procedure)	5.03 5.03 9.91 7.97 3.79 5.03 5.03 4.87 1.10
84080 isoenzymes 84081 Phosphatidylglycerol (separate procedure)	9.91 7.97 3.79 5.03 5.03 4.87 1.10 6.00
84081 Phosphatidylglycerol (separate procedure)	7.97 3.79 5.03 5.03 4.87 1.10
	3.79 5.03 5.03 4.87 1.10 6.00
X/IIX/ Phochhohovoca icomaraca	5.03 5.03 4.87 1.10 6.00
·	5.03 4.87 1.10 6.00
	4.87 1.10 6.00
,	1.10 5.00
	6.00
!	
	5.94
•	5.03
	5.03
(For pregnancy test, use 81025 or 84703)	
,	7.32
84140 Pregnenolone 23	3.09
84143 17-hydroxypregnenolone 29	9.23
84144 Progesterone 23	3.09
(For 17-hydroxyprogesterone, use 83498)	
	5.00
	4.35
,	4.35
,	4.35
	5.03
,	5.03
(see Rule 11)	5.03
	5.03
	2.37
	3.00
	1.25
	9.00
, , , , , , , , , , , , , , , , , , , ,	4.90
•	3.04
1 37	7.50
1 3	4.45
	3.99 5.03
, , ,	5.03 5.03
·	5.03
(Somatotropin, see 83003)	,.00
	0.50
	7.09

CODE	DESCRIPTION	<u>FEE</u>
84376	Sugars (mono-,di-,and oligosaccharides); single qualitative, each specimen	5.03
84377	multiple qualitative, each specimen	7.61
84378	single quantitative, each specimen	15.32
84379	multiple quantitative, each specimen	15.92
84402	Testosterone; free	30.54
84403	total	34.40
84425	Thiamine (Vitamin B-1)	15.00
84436	Thyroxine; total	5.70
84439	free	9.00
84442	Thyroxine binding globulin (TBG)	9.00
84443	Thyroid stimulating hormone (TSH)	9.00
84446	Tocopherol alpha (Vitamin E)	18.90
84449	Transcortin (cortisol binding globulin)	18.45
84450	Transferase; aspartate amino (AST)(SGOT) (see Rule 11)	5.03
84460	alanine amino (ALT)(SGPT) (see Rule 11)	5.03
84466	Transferrin	12.50
84478	Triglycerides (see Rule 11)	5.03
84479	Thyroid hormone (T3 or T4) uptake (with or without) thyroid	3.30
	hormone binding ratio (THBR)	
84480	Triiodothyronine T3; total (TT-3)	5.70
84481	free	9.00
84482	reverse	5.70
84484	Troponin, quantitative	8.05
84510	Tyrosine	14.38
84512	Troponin, qualitative	5.20
84520	Urea nitrogen; quantitative (see Rule 11)	5.03
84540	urine (see Rule 11)	5.03
84550	Uric acid; blood (see Rule 11)	5.03
84560	other source (see Rule 11)	5.03
84585	Vanillylmandelic acid (VMA), urine	20.00
84588	Vasopressin (antidiuretic hormone, ADH)	34.07
84590	Vitamin A	14.60
84591	Vitamin, not otherwise specified	BR
84597	Vitamin K	18.95
84620	Xylose absorption test, blood and/or urine	13.85
84630	Zinc	7.90
84681	C-peptide	21.72
84702	Gonadotropin, chorionic (HCG); quantitative (see Rules 9 and 15)	12.37
84703	qualitative (see Rule 9)	2.00

		Laboratory Fee Sci	ledule	
CODE		DESCRIPTION		FEE
84999	Unlisted chemistry/genetic testing procedure (See Rule 3) (Reimbursement is limited to the listed analytes for the purpose of providing information for diagnosis or monitoring of genetic disease or carrier state. Clinical applications other than genetic testing are subject to a coverability determination for unlisted procedures.)		BR	
Alpi Acid I Acyl-(Mer Sho Aden Aldola Argin Arylsi ATPa Citrat Cytoc Dihyo Dystr Enola Fatty	osuccinase ulfatase A,B and/or C se e Synthase chrome Oxidase lropteridine Reductase ophin	Fumarase Galactocerebrosidase, Beta Galactose –4- Sulfatase Galactose –6- Sulfatase Galactosidase, Alpha and/or Beta Glucocerebrosidase, Beta Glucuronidase, Beta Glyceraldehyde –3-P- Dehydrogenase Glycerophosphate Dehydrogenase, Alpha Hexosaminidase, A Iduronidase, alpha Iduronosulfatase Mannosidase, Alpha and/or Beta Myoadenylate Deaminase NADH Cytochrome C Reductase NADH Dehydrogenase	Neuraminidase Nucleoside Phosphorylase Ornithine Carbamyl Transferase (OCT) Phosphofructokinase Phosphoglucomutase, Isoenzymes Phosphoglycerate Kinase Phosphoglycerate Mutase Phosphorylase Phosphorylase Phosphorylase B Kinase Phytanic acid Pyruvate Decarboxylase Sphingomyelinase Succinate Cytochrome C Reductase Succinate Dehydrogenase Sulfaminidase Triose phosphate Isomerase	
HEMA	TOLOGY and	COAGULATION		
85002 85004 85007	blood smea	omated differential WBC co r, microscopic examination	with manual differential	3.00 3.17 1.43
85013	spun microl	(includes RBC morphology	and platelet estimation)	2.00
85014	hematocrit	ioniato on		2.00
85018	hemoglobin	(Hgb)		2.00
85025		CBC), automated (Hgb, Hct nt), and automated different		3.17
85027	complete (C platelet cou	CBC), automated (Hgb, Hct nt)	, RBC, WBC and	3.17
85032		count (erythrocyte, leukocy	te, or platelet) each	2.00
85041		ell (RBC), automated		3.17
85044	reticulocyte			1.43
85045	•	, automated		3.17
85046	parameters	s, automated, including one (eg reticulocyte hemoglobir eticulocyte volume (MRV), R ent	n content (CHr),	1.43
85048	leukocyte (\	NBC), automated		3.17
85049	platelet, aut			3.17
$0E \cap EE$	Deticulated plate	lot accay		22 47

85055 Reticulated platelet assay

23.17

CODE	DESCRIPTION	FEE
85060	Blood smear, peripheral,(including) interpretation by physician with written report	20.22
85097	Bone marrow; smear interpretation (For bone marrow biopsy or cell block interpretation, use 88305)	20.22
85210	Clotting; factor II, prothrombin, specific	14.48
85220	factor V (AcG or proaccelerin), labile factor	19.30
85230	factor VII (proconvertin, stable factor)	19.90
85240	factor VIII (AHG), one stage	9.40
85244	factor VIII related antigen	9.40
85245	factor VIII, VW factor, ristocetin cofactor	9.40
85246	factor VIII, VW factor antigen	9.40
85247	factor VIII, Von Willebrand factor, multimetric analysis	11.77
85250	factor IX (PTC or Christmas)	19.90
85260	factor X (Stuart-Prower)	19.30
85270	factor XI (PTA)	19.30
85280	factor XII (Hageman)	19.90
85290	factor XIII (fibrin stabilizing)	7.93
85291	factor XIII (fibrin stabilizing), screen solubility	7.10
85292	prekallikrein assay (Fletcher factor assay)	24.28
85293	high molecular weight kininogen assay (Fitzgerald factor assay)	24.28
85300	Clotting inhibitors or anticoagulants; antithrombin III, activity	9.43
85301	antithrombin III, antigen assay	13.85
85302	protein C, antigen	15.41
85303	protein C, activity	15.41
85305	protein S, total	15.41
85306	protein S, free	15.41
85307	Activated Protein C (APC) resistance assay	14.73
85335	Factor inhibitor test	13.53
85337	Thrombomodulin	13.68
85347	Coagulation time; activated	5.40
85348	other methods	5.15
85360	Euglobulin lysis	6.60
85362	Fibrin(ogen) degradation (split) products (FDP) (FSP); agglutination slide, semiquantitative	9.52
85366	paracoagulation	7.58
85370	quantitative	9.00
85378	Fibrin degradation products, D-dimer; qualitative or semiquantitative	9.90
85379	quantitative	10.61
85380	ultrasensitive (eg. for evaluation for venous thromboembolism), qualitative or semiquantitative	10.61
85384	Fibrinogen; activity	6.90
85385	antigen	6.90
85441	Heinz bodies; direct	5.20
85445	induced, acetyl phenylhydrazine	5.20
	(For hemoglobin, see 83020-83051)	

CODE	DESCRIPTION	<u>FEE</u>
85460	Hemoglobin or RBCs, fetal, for fetomaternal hemorrhage; differential lysis (Kleihauer-Betke)	10.69
85461	rosette	9.38
85475	Hemolysin, acid	12.26
85520	Heparin assay	16.53
85536	Iron stain, peripheral blood	8.15
	(For iron stains on bone marrow smears, use code 88313) (For Leder (esterase) stain, use 88319)	
85540	Leukocyte alkaline phosphatase with count	10.40
	(For LE factor by latex, use 86235; for lupus anticoagulant, se 85613, 85705)	ee
85549	Muramidase	20.77
85555	Osmotic fragility, RBC; unincubated	8.29
85557	incubated	9.43
85576	Platelet; aggregation (in vitro), each agent	10.71
85610	Prothrombin time	3.91
85612	Russell viper venom time (includes venom); undiluted	7.82
85613	diluted	7.82
85635	Reptilase test	8.48
85651	Sedimentation rate, erythrocyte; non-automated	2.00
85652	automated	2.00
85670	Thrombin time; plasma	5.30
85705	Thromboplastin inhibition; tissue	7.61
85730	Thromboplastin time, partial (PTT); plasma or whole blood	6.19
85732	substitution, plasma fractions, each	6.19
85810	Viscosity	12.21

IMMUNOLOGY

Immunologic tests for antigen or antibody should be reported using the most specific code available. For infectious agent antibody or antigen tests, see codes 86602 – 86793 and the cross-references located in that coding range. See Rules 6 and 10. For antigen identification in solid tissue, see 88342-88347 in Surgical Pathology.

86038	Antinuclear antibodies (ANA);	5.20
86039	titer	5.20
86060	Antistreptolysin 0; titer	5.20
86063	screen	3.75
86140	C-reactive protein;	4.10
86141	high sensitivity (hsCRP)	10.25
86146	Beta 2 Glycoprotein 1 antibody, each	7.82
86147	Cardiolipin (phospholipid) antibody, each Ig class	7.82
86148	Anti-phosphatidylserine (phospholipid) antibody	7.82
86157	Cold agglutinin; titer	5.20

CODE	DESCRIPTION	<u>FEE</u>
86160	Complement; antigen, each component	10.50
86161	functional activity, each component	15.82
86162	total hemolytic (CH50)	19.39
86215	Deoxyribonuclease, antibody	5.20
86225	Deoxyribonucleic acid (DNA) antibody; native or double stranded	5.20
86235	Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Scl70, J01), each antibody	5.20
86255	Fluorescent noninfectious agent antibody; screen, each antibody, (not elsewhere specified) (see Rule 10)	5.20
86256	titer, each antibody (not elsewhere specified) (see Rule 10)	BR
86294	Immunoassay for tumor antigen, qualitative or semiquantitative	8.03
06200	(eg, bladder tumor antigen)(see Rule 15)	24.25
86300	Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) (see Rule 15)	24.35
86301	CA 19-9 (see Rule 15)	24.35
86304	CA 125 (see Rule 15)	24.35
86308	Heterophile antibodies; screening	4.73
86309	titer	7.50
86316	Immunoassay for tumor antigen; other antigen, quantitative, (eg, CA	BR
	50,72-4, 549), each (not elsewhere specified) (see Rule 15)	
	(For measurement of serum HER-2/neu oncoprotein, see 83950)	
	(For quantitative immunoassay of infectious agent antibody, use the	
86318	organism specific codes 86602 et seq.) Immunoassay for infectious agent antibody, qualitative or	3.75
00310	semiquantitative, single step method (not elsewhere specified)	5.75
	(eg, reagent strip)	
	(For Streptococcus screen, see 86063 or 87880)	
86320	Immunoelectrophoresis; serum	27.42
86325	other fluids (eg, urine, cerebrospinal fluid) with concentration	27.42
86329	Immunodiffusion; not elsewhere specified	12.50
00020	(For quantitation of antigenic complement, eg, C2 or C3, use 86160)	12.00
86334	Immunofixation electrophoresis; serum	27.42
86335	other fluids with concentration (eg, urine, CSF)	30.67
86336	Inhibin A	6.50
86337	Insulin antibodies	12.50
86340	Intrinsic factor antibodies	11.36
86341	Islet cell antibody (see Rule 19)	12.50
86355	B cells, total count (see Rule 18)	23.17
86357	Natural killer (nk) cells, total count (see Rule 18)	23.17
86359	T cells; total count	23.17
86360	absolute CD4 and CD8 count, including ratio	64.93
86361	absolute CD4 count	23.17
	(For T-cell immunophenotyping, see Rule 18)	
86367	Stem cells (ie, CD34), total count (see Rule 18)	23.17
86376	Microsomal antibodies (eg, thyroid or liver-kidney), each	14.91

CODE	DESCRIPTION	<u>FEE</u>
86382	Neutralization test, viral	5.00
86403	Particle agglutination; screen, each antibody	3.75
86430	Rheumatoid factor; qualitative	4.88
86431	quantitative	5.20
86592	Syphilis test; qualitative (eg, VDRL, RPR, ART)	3.27
86593	quantitative (includes screen and titer)	3.70
	(For infectious agent antibody or antigen tests not listed by name,	
	see Rule 10 A, B; for maximum reimbursable amounts for two or more infectious agent tests, see Rule 6C.)	
86602	Antibody; actinomyces	8.03
86603	adenovirus	8.03
86606	Aspergillus	8.03
86609	bacterium, not elsewhere specified	BR
86611	Bartonella	8.03
86612	Blastomyces	8.03
86615	Bordetella	8.03
86617	Borrelia burgdorferi (Lyme disease) confirmatory test	17.13
	(eg, Western blot or immunoblot)	
86618	Borrelia burgdorferi (Lyme disease)	18.83
86619	Borrelia (relapsing fever)	14.79
86622	Brucella	8.03
86625	Campylobacter	8.03
86631	Chlamydia	8.03
86632	Chlamydia, IgM	8.03
86635	Coccidioides	8.03
86638	Coxiella brunetii (Q fever)	8.03
86641	Cryptococcus	8.03
86644	cytomegalovirus (CMV)	15.91
86645	cytomegalovirus (CMV), IgM	8.03
86651 86652	encephalitis, California (La Crosse)	8.03 8.03
86653	encephalitis, Eastern equine encephalitis, St. Louis	8.03
86654	encephalitis, St. Louis encephalitis, Western equine	8.03
86658	enterovirus (eg, coxsackie, echo, polio)	8.03
86663	Epstein-Barr (EB) virus, early antigen (EA)	14.50
86664	Epstein-Barr (EB) virus, nuclear antigen (EBNA)	16.91
86665	Epstein-Barr (EB) virus, viral capsid (VCA)	20.06
86666	Ehrlichia	8.03
86668	Francisella tularensis	11.50
86671	fungus, not elsewhere specified	BR
86674	Giardia Lamblia	16.27
86677	Helicobacter pylori	8.03
86682	helminth, not elsewhere specified	BR
	(For fecal hemoglobulin detection by immunoassay, use 82274)	
86684	Hemophilus influenza	17.52

CODE	DESCRIPTION	FEE
86687	HTLV-I	9.28
86689	HTLV or HIV antibody, confirmatory test (eg, Western Blot)	26.75
86692	hepatitis, delta agent	18.98
86696	herpes simplex, type 2	14.50
86698	histoplasma	12.41
86701	HIV-1	12.27
86702	HIV-2	14.95
86703	HIV-1 and HIV-2, single assay (For maximum reimbursable amounts for hepatitis tests performed in combination, see Rule 6C)	15.17
86704	Hepatitis B core antibody (HBcAb), total	10.10
86705	IgM antibody	10.10
86706	Hepatitis B surface antibody (HBsAb)	10.10
86707	Hepatitis Be antibody (HBeAb)	10.10
86708	Hepatitis A antibody (HAAb), total	10.00
86709	IgM antibody	10.00
86710	Antibody; influenza virus	14.99
86713	Legionella	16.92
86717	Leishmania	8.03
86720	Leptospira	8.03
86723	Listeria monocytogenes	8.03
86727	lymphocytic choriomeningitis	8.03
86729	Lymphogranuloma Venereum	8.03
86735	mumps	8.03
86738	Mycoplasma	14.65
00=44	(For Neisseria gonorrhoeae antigen, see 87590 or 87591)	
86741	Neisseria meningitidis	8.03
86744	Nocardia	8.03
86747	parvovirus	16.62
86750	Plasmodium (malaria)	14.58
86753 86756	protozoa, not elsewhere specified	BR 8.03
86757	respiratory syncytial virus Rickettsia	21.40
86759	rotavirus	14.58
86762	rubella	15.91
86765	rubeola	14.25
86768	Salmonella	9.05
86771	Shigella	8.03
00	(For Streptococcus direct screen, see 87880)	0.00
86777	Toxoplasma	15.91
86778	Toxoplasma, IgM	14.12
86781	Treponema pallidum, confirmatory test (eg, FTA-abs)	12.63
	(For syphilis screen, see 86592, 86593)	
86784	trichinella	8.03
86787	varicella-zoster	8.03

CODE	DESCRIPTION	FEE
86790 86793 86800 86803 86804	virus, not elsewhere specified Yersinia Thyroglobulin antibody Hepatitis C antibody; confirmatory test (eg, immunoblot) (For thyroid autoantibodies, use 86376)	BR 8.03 13.35 10.00 27.27
TRAN	SFUSION MEDICINE	
86850 86860 86870 86880	Antibody screen, RBC, each serum technique Antibody elution (RBC), each elution Antibody identification, RBC antibodies, each panel for each serum technique Antihuman globulin test (Coombs test); direct, each antiserum	5.55 11.70 14.10 4.69
86900 86901 86905 86940 86941	Blood typing; ABO Rh(D) RBC antigens, other than ABO or Rh(D), each Hemolysins and agglutinins; auto, screen, each incubated	4.22 4.20 4.60 7.14 10.27
MICRO	OBIOLOGY	
87015 87040	Concentration(any type), for infectious agents Culture, bacterial; blood, aerobic, with isolation and presumptive identification of isolates (includes anaerobic culture, if appropriate)	3.25 8.15
87045	stool, aerobic, with isolation and preliminary examination (eg, KIA, LIA), Salmonella and Shigella species	8.15
87046	stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate	2.95
87070	any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates (For urine, use 87086 - 87088)	8.15
87075	any source, except blood, anaerobic with isolation and presumptive identification of isolates	11.08
87076	anaerobic isolate, additional methods required for definitive identification, each isolate	9.70
87077	aerobic isolate, additional methods required for definitive identification, each isolate	9.70
87081	Culture, presumptive, pathogenic organisms, screening only	5.20
87086	Culture, bacterial; quantitative colony count, urine	8.15
87088	with isolation and presumptive identification of isolates, urine	9.70
87101	Culture, fungi (mold or yeast)isolation, with presumptive identification of isolates; skin, hair, or nail	9.43
87102	other source (except blood)	10.75
87103	blood	11.37

CODE	DESCRIPTION	FEE
87106	Culture, fungi, definitive identification, each organism; yeast (use in addition to codes 87101, 87102, or 87103 when appropriate)	9.70
87107	mold	9.70
87109	Culture, mycoplasma, any source	8.15
87110	Culture, chlamydia, any source	8.15
87116	Culture, tubercle or other acid-fast bacilli (eg, TB, AFB,	14.90
	mycobacteria) any source, with isolation and presumptive identification of isolates	
87118	Culture, mycobacterial, definitive identification, each isolate	15.00
87164	Dark field examination, any source (eg, penile, vaginal, oral, skin);	8.00
	includes specimen collection	
87166	without collection	8.00
87169	Macroscopic examination; parasite	2.00
87172	Pinworm exam (eg, cellophane tape prep)	2.00
87177	Ova and parasites, direct smears, concentration and identification	12.24
87181	Susceptibility studies, antimicrobial agent; agar dilution method,	4.50
	per agent (eg, antibiotic gradient strip)	
87184	disk method, per plate (12 or fewer agents)	6.59
87185	enzyme detection (eg, beta lactamase), per enzyme	4.50
87186	microdilution or agar dilution(minimum inhibitory concentration (MIC) or breakpoint), each multi-antimicrobial, per plate	6.59
87188	macrobroth dilution method, each agent	4.50
87190	mycobacteria, proportion method, each agent	7.81
87205	Smear, primary source with interpretation;	3.40
	Gram or Giemsa stain for bacteria, fungi or cell types	
87206	fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types	5.85
87207	special stain for inclusion bodies or parasites (eg, malaria, coccidia, microsporidia, trypanosomes, herpes viruses)	7.00
87209	complex special stain (eg, trichrome, iron hemotoxylin) for ova and parasites	5.85
87210	wet mount for infectious agents (eg, saline, India ink, KOH preps) (Does not include KOH on skin, hair or nails)	3.40
87230	Toxin or antitoxin assay, tissue culture (eg, Clostridium difficile toxin)	9.40

CODE	DESCRIPTION	FEE
87250	Virus isolation; inoculation of embryonated eggs, or small animal, includes observation and dissection	27.03
87252	tissue culture inoculation, observation, and presumptive identification by cytopathic effect	31.84
87253	tissue culture, additional studies or definitive identification (eg. hemabsorption, neutralization, immunofluorescence stain), each isolate	23.47
87254	centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	6.76
87255	including identification by non-immunologic method, other than by cytopathic effect (eg. virus specific enzymatic activity)	6.76
87260	Infectious agent antigen detection by immunofluorescent technique; adenovirus	8.03
87265	Bordetella pertussis/parapertussis	8.03
87269	giardia	16.27
87270	Chlamydia trachomatis	8.03
87271	Cytomegalovirus, direct fluorescent antibody (DFA)	14.50
87272	cryptosporidium	16.27
87273	Herpes simplex virus type 2	14.50
87274	Herpes simplex virus type 1	14.50
87275	Infectious agent antigen detection by immunofluorescent technique; influenza B virus	14.50
87276	influenza A virus (for rapid flu test, use 87804)	14.50
87278	Legionella pneumophila	16.92
87279	Parainfluenza virus, each type	8.03
87280	respiratory syncytial virus	8.03
87281	Pneumocystis carinii	8.03
87290	Varicella zoster virus	8.03
87299	not otherwise specified, each organism (see Rule 10B)	21.43
87301	Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple step method; adenovirus enteric types 40/41	8.03
87320	Chlamydia trachomatis	8.03
87324	Clostridium difficile toxin(s)	9.40
87327	Cryptococcus neoformans	8.03
87328	cryptosporidium	16.27
87329	giardia	16.27
87332	cytomegalovirus	15.91
87335	Escherichia coli 0157	9.05
87336	Entamoeba histolytica dispar group	8.03
87337	Entamoeba histolytica group	8.03
87338	Helicobacter pylori, stool	8.03
87340	hepatitis B surface antigen (HBsAg)	11.10
87341	hepatitis B surface antigen (HBsAg) neutralization	11.10
87350	hepatitis Be antigen (HBeAg)	10.10
07330	nepatitis de antigen (ndeng)	10.10

CODE	DESCRIPTION	FEE
87380	hepatitis, delta agent	10.00
87385	Histoplasma capsulatum	12.41
87390	HIV-1 (eg, P24 antigen)	21.90
87420	respiratory syncytial virus	8.03
87425	rotavirus	14.58
87427	Shiga-like toxin	14.08
87430	Streptococcus, group A	5.20
	(For streptococcus screen, see 87880)	
87449	Infectious agent antigen detection by enzyme immunoassay	5.20
	technique qualitative or semiquantitative; multiple step method, not	
07450	otherwise specified, each organism	0.75
87450	single step method, not otherwise specified, each organism	3.75
87476	Infectious agent detection by nucleic acid (DNA or RNA);	21.43
07400	Borrelia burgdorferi, amplified probe technique	0.02
87480 87486	Candida species, direct probe technique Chlamydia pneumoniae, amplified probe technique	8.03 21.43
87490	Chlamydia trachomatis, direct probe technique	8.03
87490	Chlamydia trachomatis, direct probe technique Chlamydia trachomatis, amplified probe technique	21.43
87495	cytomegalovirus, direct probe technique	15.91
87510	Gardnerella vaginalis, direct probe technique	8.03
87516	hepatitis B virus, amplified probe technique	21.43
87521	hepatitis C, amplified probe technique	48.00
87522	hepatitis C, quantification	59.20
87535	HIV-1, amplified probe technique	21.43
87536	HIV-1, quantification	117.59
87551	Mycobacteria species, amplified probe technique	75.00
87556	Mycobacteria tuberculosis, amplified probe technique	75.00
87561	Mycobacteria avium-intracellulare, amplified probe technique	75.00
87581	Mycoplasma pneumoniae, amplified probe technique	21.43
87590	Neisseria gonorrhoeae, direct probe technique	8.03
87591	Neisseria gonorrhoeae, amplified probe technique	21.43
87620	papillomavirus, human, direct probe technique	15.91
87621	papillomavirus, human, amplified probe technique	27.85
87650	Streptococcus, group A, direct probe technique	6.58
87660	Trichomonas vaginalis, direct probe technique	21.43
87797	Infectious agent detection by nucleic acid (DNA or RNA),	BR
07700	not otherwise specified; direct probe technique, each organism	DD
87798	amplified probe technique, each organism	BR
87800	Infectious agent detection by nucleic acid(DNA or RNA), multiple organisms; direct probe(s) technique	16.10
87801	amplified probe(s) technique	40.00
87803	Infectious agent antigen detection by immunoassay with direct optical observation; Clostridium difficile toxin A	9.40
87804	influenza	14.50
87807	respiratory syncytial virus	14.50

CODE	DESCRIPTION	FEE
87880	Infectious agent detection by immunoassay with direct optical observation; Streptococcus, group A	3.75
87899	not otherwise specified	8.03
87900	Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics	80.00
87901	Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV 1, reverse transcriptase and protease	350.00
87902	Hepatitis C virus	350.00
87903	Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested	675.29
87904	each additional drug tested (list separately in addition to code for primary procedure)	7.20
CYTO	PATHOLOGY	
88104	Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation	19.12
88106	filter method only with interpretation	19.12
88107	smears and filter preparation with interpretation	19.12
88108	Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)	19.12
88112	Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal	28.82
	(Do not report 88112 with 88108)	
88141	Cytopathology, cervical or vaginal (any reporting system); requiring interpretation by physician (List separately in addition to code for	8.30
88142	technical service) Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual	24.46
00110	screening under physician supervision	24.42
88143	with manual screening and rescreening under physician supervision	24.46
88147	Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision	14.76
88148	screening by automated system with manual re-screening under physician supervision	14.76
88150	Cytopathology, slides, cervical or vaginal; manual screening under physician supervision	14.76
88153	with manual screening and rescreening under physician supervision	14.76
88160	Cytopathology, smears, any other source (specify); screening and interpretation	19.12
88161 88162	preparation, screening and interpretation extended study involving over 5 slides and/or multiple stains	19.12 19.12

CODE	DESCRIPTION	<u>FEE</u>
88164	Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision	14.76
88165	with manual screening and rescreening under physician supervision	14.76
88173	Cytopathology, evaluation of fine needle aspirate; interpretation and report	19.12
88174	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision	29.85
88175	with screening by automated system and manual rescreening or review under physician supervision (See Rule 22 for instrumented PAP screening definitions)	37.01
88184	,	23.17
88185	each additional marker (list separately in addition to code for first marker)	15.45
88187 88188 88189	interpretation; 2 to 8 markers interpretation; 9 to 15 markers interpretation; 16 or more markers	20.00 25.00 30.00

CYTOGENETIC STUDIES

Cytogenetic studies procedure codes 88245, 88267 and 88269 must be billed in combination with procedure code 88280 to report a 2-karyotype chromosome analysis as described in the quality control standards for cytogenetic licensure.

(For acetylcholinesterase, use 82013)

(For alpha-fetoprotein, serum or amniotic fluid, use 82105, 82106)

88230	Tissue culture for non-neoplastic disorders; lymphocyte	40.00
88233	skin or other solid tissue biopsy	31.91
88235	amniotic fluid or chorionic villus cells	131.91
88237	Tissue culture for neoplastic disorders; bone marrow, blood cells	100.03
88239	solid tumor	131.91
88245	Chromosome analysis for breakage syndromes; baseline Sister	90.00
	Chromatid Exchange (SCE), 20-25 cells	
88248	baseline breakage, score 50-100 cells, count 20 cells, 2	100.00
	karyotypes (eg, for ataxia telangiectasia, Fanconi anemia,	
	fragile X)	
88249	score 100 cells, clastogen stress (eg, diepoxybutane,	100.00
	mitomycin C, ionizing radiation, UV radiation)	
88262	Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding	100.00
88263	count 45 cells for mosaicism, 2 karyotypes, with banding	100.00
88267	Chromosome analysis, amniotic fluid or chorionic villus, count 15	90.00
	cells, 1 karyotype, with banding	

CODE	DESCRIPTION	<u>FEE</u>
88269	Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding	75.00
88271	Molecular cytogenetics; DNA probe, each (eg. FISH)	29.60
88272	chromosomal in situ hybridization, analyze 3-5 cells (eg. for derivatives and markers)	37.00
88273	chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)	44.40
88274	interphase in situ hybridization, analyze 25-99 cells	48.10
88275	interphase in situ hybridization, analyze 100-300 cells	55.50
88280	Chromosome analysis; additional karyotypes, each study (use in addition to code 88267, 88269)	10.00
88285	additional cells counted, each study (use in addition to code 88269)	5.00
88291	Cytogenetics and molecular cytogenetics, interpretation and report	20.00

SURGICAL PATHOLOGY

Surgical pathology procedure codes are reimbursable per specimen. A specimen is defined as tissue or tissues that is (are) submitted for individual and separate attention, requiring individual examination and pathologic diagnosis. Any unlisted specimen should be assigned to the code which most closely reflects the work involved when compared to other specimens assigned to that code.

88302 LEVEL II - Surgical pathology, gross and microscopic examination 13.26

Appendix, Incidental Fallopian Tube, Sterilization Fingers/Toes, Amputation, Traumatic Foreskin, Newborn Hernia Sac, Any Location Hydrocele Sac Nerve

Diverticulum -

Skin, Plastic Repair Sympathetic Ganglion Testis, Castration Vaginal Mucosa, Incidental Vas Deferens, Sterilization

88304 LEVEL III - Surgical pathology, gross and microscopic examination 18.72

Abortion, Induced Abscess Aneurysm - Arterial/Ventricular Anus, Tag Appendix, Other than Incidental Artery, Atheromatous Plaque Bartholin's Gland Cyst Bone Fragment(s), Other than Pathologic Fracture Bursa/Synovial Cyst Carpal Tunnel Tissue Cartilage, Shavings Cholesteatoma Colon, Colostomy Stoma Conjunctiva - Biopsy/Pterygium Cornea

Esophagus/Small Intestine Dupuytren's Contracture Tissue Femoral Head, Other than Fracture Fissure/Fistula Foreskin, Other than Newborn Gallbladder **Ganglion Cyst** Hematoma Hemorrhoids Hydatid of Morgagni Intervertebral Disc Joint, Loose Body Meniscus Mucocele, Salivary

Neuroma-Morton's/Traumatic Pilonidal Cyst/Sinus Polyps, Inflammatory -Nasal/Sinusoidal Skin - Cyst/Tag/Debridement Soft Tissue, Debridement Soft Tissue, Lipoma Spermatocele Tendon/Tendon Sheath Testicular Appendage Thrombus or Embolus Tonsil and/or Adenoids Varicocele Vas Deferens, Other than Sterilization

Vein, Varicosity

CODE DESCRIPTION FEE

88305 LEVEL IV - Surgical pathology, gross and microscopic examination

Abortion - Spontaneous/

Missed Artery, Biopsy Bone Marrow, Biopsy Bone, Exostosis

Brain/Meninges, Other than For Tumor Resection Breast, Biopsy, Not Requiring Microscopic Evaluation of

Surgical Margins

Breast, Reduction Mammoplasty

Bronchus, Biopsy Cell Block, Any Source Cervix, Biopsy

Colon, Biopsy Duodenum, Biopsy

Endocervix, Curettings/Biopsy Endometrium Curettings/Biopsy Esophagus, Biopsy Extremity, Amputation,

Traumatic

Fallopian Tube, Biopsy Fallopian Tube. **Ectopic Pregnancy** Femoral Head, Fracture Finger/Toes, Amputation,

Non-traumatic

Gingiva/Oral Mucosa, Biopsy

Heart Valve Joint, Resection Kidney, Biopsy Larynx, Biopsy

Leiomyoma (s), Uterine Myomectomy without Uterus Lip. Biopsy/Wedge Resection Lung, Transbronchial Biopsy Lymph Node, Biopsy

Muscle, Biopsy Nasal Mucosa, Biopsy Nasopharynx/Oropharynx,

Biopsy Nerve, Biopsy

Odontogenic/Dental Cvst

Omentum, Biopsy

Ovary with or without Tube,

Non-neoplastic Ovary, Biopsy/ Wedge Resection Parathyroid Gland Peritoneum, Biopsy Pituitary Tumor Placenta, Other than Third Trimester Pleura/Pericardium-Biopsy/Tissue

Polyp, Cervical/Endometrial

Polyp, Colorectal

Polyp, Stomach/Small Intestine

Prostate, Needle Biopsy

Prostate, TUR

Salivary Gland, Biopsy Sinus, Paranasal Biopsy Skin, Other than Cyst/Tag/ Debridement/Plastic Repair Small Intestine, Biopsy

Soft Tissue, Other than

Tumor/Mass/Lipoma/Debridement

Spleen

Stomach, Biopsy

Synovium

Testis, Other than Tumor/ Biopsy/Castration Thyroglossal Duct/Brachial

Cleft Cyst Tongue, Biopsy Tonsil, Biopsy Trachea, Biopsy Ureter, Biopsy Urethra, Biopsy Urinary Bladder, Biopsy Uterus, with or without Tubes & Ovaries. for Prolapse

Vagina, Biopsy Vulva/Labia, Biopsy

88307 LEVEL V - Surgical pathology, gross and microscopic examination

18.72

18.72

Adrenal, Resection Bone - Biopsy/Curettings Bone Fragment(s), Pathologic Fracture Brain, Biopsy Brain/Meninges, **Tumor Resection** Breast, Excision of Lesion, Requiring Microscopic **Evaluation of Surgical** Margins

Breast, Mastectomy -Partial/Simple

Cervix, Conization

Colon, Segmental Resection, Other than for Tumor Extremity, Amputation, Non-traumatic Eye, Enucleation

Kidney, Partial/Total Nephrectomy Larynx, Partial/Total Resection Liver, Biopsy Needle/Wedge Liver, Partial Resection Lung, Wedge Biopsy Lymph Nodes, Regional Resection

Mediastinum, Mass Myocardium, Biopsy Odontogenic Tumor Ovary with or without Tube, Neoplastic Pancreas, Biopsy

Placenta, Third Trimester Prostate, Except Radical

Resection

Salivary Gland Sentinel Lymph Node Small Intestine, Resection, Other than for Tumor Soft Tissue Mass (except Lipoma) - Biopsy/Simple Excision

Stomach - Subtotal/Total Resection, Other than

for Tumor Testis, Biopsy Thymus, Tumor Thyroid, Total/Lobe Ureter, Resection Urinary Bladder, TUR

Uterus, with or without Tubes and

Ovaries, Other than Neoplastic/Prolapse

CODE		DESCRIPTION		<u>FEE</u>
88309	LEVEL VI - Surgical pat	hology, gross and m	icroscopic examination	18.72
Breast, Regio Colon, for Tu Colon, Esopha Total Extrem Fetus, Larynx, Resec	Mastectomy - with nal Lymph Nodes Pa Segmental Resection Front Pr Total Resection Sagus, Partial/ Resection ity, Disarticulation Student Processing Proces	ing - Total/Lobe/ Segment Resection ancreas - Total/Subtotal Resection ostate, Radical Resection mall Intestine, Resection for Tumor fit Tissue Tumor, Extensive Resection omach - Subtotal/Total Resection, Tumor	Testis, Tumor Tongue/Tonsil - Resection for Tumor Urinary Bladder, Partial/ Total Resection Uterus, with or without Tubes & Ovaries, Neoplastic Vulva - Total/ Subtotal Resection	
88312	Special stains (List separately in addition to code for primary service); Group I for microorganisms (eg, Gridley, acid fast, methenamine silver), each			13.18
88313	Group II, all other ((eg, iron, trichrome), stry and immunopero	•	9.88
88319	Determinative histochemistry or cytochemistry to identify enzyme constituents, each			35.19
88342	Immunohistochemistry (including tissue immunoperoxidase), each antibody (For immunophenotyping, see Rule 18)			25.37
88346 88347 88360	Immunofluorescent study, each antibody; direct method indirect method		19.25 19.25 25.37	
88361	using computer as	sisted technology (co 88361 with 88342 u -embedded sections ometric analysis, only orted; if performed as	omputer generated) nless each procedure is are performed in y the morphometric an independent	25.37

CODE	<u>DESCRIPTION</u>	<u>FEE</u>
OTHER	R PROCEDURES	
89050	Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except blood;	2.80
89051	with differential count	2.80
89055	Leukocyte assessment, fecal, qualitative or semiquantitative	3.40
89060	Crystal identification by light microscopy with or without polarizing lens analysis, any body fluid (except urine)	6.00
89190	Nasal smear for eosinophils	4.70
89230	Sweat collection by iontophoresis (includes analysis)	6.38
89321	Semen analysis, presence and/or motility of sperm	6.80
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge (Limited to home bound phlebotomy; see Rule 23)	7.50